» Articles » PMID: 15072953

Preconditioning Protects by Inhibiting the Mitochondrial Permeability Transition

Overview
Date 2004 Apr 10
PMID 15072953
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial permeability transition (mPT) is a crucial event in the progression to cell death in the setting of ischemia-reperfusion. We have used a model system in which mPT can be reliably and reproducibly induced to test the hypothesis that the profound protection associated with the phenomenon of myocardial preconditioning is mediated by suppression of the mPT. Adult rat myocytes were loaded with the fluorescent probe tetramethylrhodamine methyl ester, which generates oxidative stress on laser illumination, thus inducing the mPT (indicated by collapse of the mitochondrial membrane potential) and ATP depletion, seen as rigor contracture. The known inhibitors of the mPT, cyclosporin A (0.2 microM) and N-methyl-4-valine-cyclosporin A (0.4 microM), increased the time taken to induce the mPT by 1.8- and 2.9-fold, respectively, compared with control (P < 0.001) and rigor contracture by 1.5-fold compared with control (P < 0.001). Hypoxic preconditioning (HP) and pharmacological preconditioning, using diazoxide (30 microM) or nicorandil (100 microM), also increased the time taken to induce the mPT by 2.0-, 2.1-, and 1.5-fold, respectively (P < 0.001), and rigor contracture by 1.9-, 1.7-, and 1.5-fold, respectively, compared with control (P < 0.001). Effects of HP, diazoxide, and nicorandil were abolished in the presence of mitochondrial ATP-sensitive K(+) (K(ATP)) channel blockers glibenclamide (10 microM) and 5-hydroxydecanoate (100 microM) but were maintained in the presence of the sarcolemmal K(ATP) channel blocker HMR-1098 (10 microM). In conclusion, preconditioning protects the myocardium by reducing the probability of the mPT, which normally occurs during ischemia-reperfusion in response to oxidative stress.

Citing Articles

Cannabinoid receptor agonist attenuates angiotensin II-induced enlargement and mitochondrial dysfunction in rat atrial cardiomyocytes.

Altieri D, Etzion Y, Anderson H Front Pharmacol. 2023; 14:1142583.

PMID: 37113758 PMC: 10126395. DOI: 10.3389/fphar.2023.1142583.


Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.

Ferdinandy P, Andreadou I, Baxter G, Botker H, Davidson S, Dobrev D Pharmacol Rev. 2023; 75(1):159-216.

PMID: 36753049 PMC: 9832381. DOI: 10.1124/pharmrev.121.000348.


Mitochondrial Quality Control in Cardiac-Conditioning Strategies against Ischemia-Reperfusion Injury.

Garcia-Nino W, Zazueta C, Buelna-Chontal M, Silva-Palacios A Life (Basel). 2021; 11(11).

PMID: 34832998 PMC: 8620839. DOI: 10.3390/life11111123.


Regulation of STAT3 and its role in cardioprotection by conditioning: focus on non-genomic roles targeting mitochondrial function.

Comita S, Femmino S, Thairi C, Alloatti G, Boengler K, Pagliaro P Basic Res Cardiol. 2021; 116(1):56.

PMID: 34642818 PMC: 8510947. DOI: 10.1007/s00395-021-00898-0.


Exosomes from neuronal stem cells may protect the heart from ischaemia/reperfusion injury via JAK1/2 and gp130.

Katsur M, He Z, Vinokur V, Corteling R, Yellon D, Davidson S J Cell Mol Med. 2021; 25(9):4455-4465.

PMID: 33797200 PMC: 8093960. DOI: 10.1111/jcmm.16515.